Novo Nordisk AS (NVO) said Tuesday that the U.S. Food and Administration has approved its Ozempic semaglutide injection which helps treat adults with type 2 diabetes.
The Danish pharmaceutical said the approval for Ozempic was based on results from a clinical trial program and follows a positive recommendation from the FDA's advisory committee in October.
Continue Reading Below
Ozempic was approved for use in two dosages of 0.5 milligrams and 1 milligram and will be launched as a pre-filled pen device, the company said.
Novo Nordisk added that it will use part of the approved requirements for the drug to conduct a trial on adolescents under 18 years old.
Write to Maryam Cockar at firstname.lastname@example.org
(END) Dow Jones Newswires
December 05, 2017 13:44 ET (18:44 GMT)